A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs AR 1001 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors AriBio
- 01 Jan 2019 Planned End Date changed from 1 Jun 2020 to 1 Aug 2020.
- 01 Jan 2019 Planned primary completion date changed from 1 Mar 2020 to 1 Jun 2020.
- 01 Jan 2019 Status changed from not yet recruiting to recruiting.